China fines domestic medicine companies for monopoly pricing | Post Online Media

The two companies have since restored regular pricing and revived market competition.

Monopoly practices in the pharmaceutical sector have been a focus of China’s anti-monopoly supervision for some time. The case will help regulate active pharmaceutical ingredient pricing and ensure a fair environment for medicine purchases and sales, according to the NDRC.

The NDRC has vowed to increase anti-monopoly supervision to protect market order, consumers and businesses.

Read complete article here:

China fines domestic medicine companies for monopoly pricing.